Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway

Show other versions (1)

Bibliographic Details
Main Authors:	Kun Wang, Albert Yu, Kewei Liu, Chunyan Feng, Yibo Hou, Jiawei Chen, Shaohua Ma, Laiqiang Huang, Xiaoyong Dai
Format:	Article
Language:	English
Published:	Wiley 2023-09-01
Series:	Advanced Science
Online Access:	https://doi.org/10.1002/advs.202305364

Similar Items

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
by: Kun Wang, et al.
Published: (2023-05-01)

Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10
by: Shan-Shan Yin, et al.
Published: (2020-07-01)

CD24-Siglec interactions in inflammatory diseases
by: Yang Liu, et al.
Published: (2023-05-01)

Lysosome‐targeting chimera (LYTAC): A silver bullet for targeted degradation of oncogenic membrane proteins
by: Qingquan Zheng, et al.
Published: (2024-03-01)

Targeting the CD24-Siglec10 Axis: A Potential Strategy for Cancer Immunotherapy
by: Junyue Fang, et al.
Published: (2024-02-01)

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
by: Kun Wang, et al.
Published: (2022-09-01)

IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins
by: Michał Mikitiuk, et al.
Published: (2023-11-01)

A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells
by: Chunyan Feng, et al.
Published: (2024-01-01)

A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer
by: Ting Deng, et al.
Published: (2023-03-01)

Siglec Ligands
by: Anabel Gonzalez-Gil, et al.
Published: (2021-05-01)

A Nucleic Acid‐Based LYTAC Plus Platform to Simultaneously Mediate Disease‐Driven Protein Downregulation
by: Yangyang Huang, et al.
Published: (2024-04-01)

Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas
by: Hesong Wang, et al.
Published: (2022-11-01)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
by: Xiuman Zhou, et al.
Published: (2023-06-01)

Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis
by: Yan Zhuang, et al.
Published: (2022-11-01)

Siglecs as Therapeutic Targets in Cancer
by: Jackwee Lim, et al.
Published: (2021-11-01)

Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.
by: Nicoll, G, et al.
Published: (1999)

Siglecs in Brain Function and Neurological Disorders
by: Shoib Sarwar Siddiqui, et al.
Published: (2019-09-01)

SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity
by: Panagiota Bouti, et al.
Published: (2023-12-01)

The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsisResearch in context
by: Roberto Lozano-Rodríguez, et al.
Published: (2023-11-01)

Discovery, Function, and Therapeutic Targeting of Siglec-8
by: Bradford A. Youngblood, et al.
Published: (2020-12-01)

Roles of the Siglec family in bone and bone homeostasis
by: Zi Ye, et al.
Published: (2023-09-01)

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
by: Chilam Chan, et al.
Published: (2023-06-01)

Induction of Siglec-FhiCD101hi eosinophils in the lungs following murine hookworm Nippostrongylus brasiliensis infection
by: Alisha Chetty, et al.
Published: (2023-05-01)

Does SIGLEC8 localize to the subcellular compartment like the Alzheimer's disease protective CD33 splice variant?
by: Chirag Dhar
Published: (2023-04-01)

Adaptation of African swine fever virus to porcine kidney cells stably expressing CD163 and Siglec1
by: Qi Gao, et al.
Published: (2022-10-01)

Lower proportion of CD19+IL-10+ and CD19+CD24+CD27+ but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
by: Karolina Stożek, et al.
Published: (2020-01-01)

Siglecs: a family of sialic-acid binding lectins.
by: Crocker, P, et al.
Published: (1998)

Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors
by: Kelli A. McCord, et al.
Published: (2024-01-01)

Expression of a Siglec-Fc Protein and Its Characterization
by: Kaijun Chi, et al.
Published: (2023-04-01)

Current Status on Therapeutic Molecules Targeting Siglec Receptors
by: María Pia Lenza, et al.
Published: (2020-12-01)

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b
by: Maria Pia Lenza, et al.
Published: (2023-06-01)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
by: Stine Sofie Frank Lende, et al.
Published: (2022-07-01)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
by: Yuhong Liu, et al.
Published: (2022-07-01)

Crystallographic and in silico analysis of the sialoside-binding characteristics of the Siglec sialoadhesin.
by: Zaccai, N, et al.
Published: (2007)

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
by: Ramya Ayyalasomayajula, et al.
Published: (2024-03-01)

First Evidence for a Role of Siglec-8 in Breast Cancer
by: Anna Trebo, et al.
Published: (2021-02-01)

Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases
by: Jannis Wißfeld, et al.
Published: (2024-03-01)

Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells
by: Piper A. Robida, et al.
Published: (2022-03-01)

Multi-omics analysis of Siglec family genes in cutaneous melanoma
by: Kezhu Li, et al.
Published: (2023-05-01)

Research progress and prospect of Siglec in innate immune cells in tumor
by: GUO Zhaoyang, HU Jingzhou
Published: (2022-12-01)